the country's leading India-based pharmaceutical company, released its March quarter performance on Friday, May 9, reporting a 22% year-on-year jump in consolidated net profit to ₹1,594 crore, beating Street estimates of ₹1,491 crore. Revenue also exceeded estimates, coming in at ₹8,506 crore compared to ₹7,083 crore in the same period last year, marking a growth of 20%. The revenue includes ₹597 crore from the acquired Consumer Healthcare business in Nicotine Replacement Therapy (NRT). Excluding the NRT business, the underlying growth was 12% year-on-year and 2% quarter-on-quarter.

#StockInNews#WatchOutFor#TechnicalViews#FundamentalViews#Miscellaneous

204 likes·83 comments